Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro

• Published in: Anticancer research 2013-05, Vol.33 (5), p.1951-1961
• Main Authors: Aderhold, Christoph, Umbreit, Claudia, Faber, Anne, Sauter, Alexander, Sommer, Jörg Ulrich, Birk, Richard, Erben, Philipp, Hofheinz, Ralf-Dieter, Stern-Straeter, Jens, Hörmann, Karl, Schultz, Johannes David
• Format: Article
• Language: English
• Subjects: Antimetabolites, Antineoplastic - pharmacology; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Biomarkers, Tumor - metabolism; Blotting, Western; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - virology; Cell Proliferation - drug effects; Cell Transformation, Viral - drug effects; Enzyme-Linked Immunosorbent Assay; Fluorouracil - pharmacology; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - metabolism; Head and Neck Neoplasms - virology; Human papillomavirus; Human papillomavirus 16 - pathogenicity; Humans; Immunoenzyme Techniques; In Vitro Techniques; Papillomavirus Infections - drug therapy; Papillomavirus Infections - metabolism; Papillomavirus Infections - virology; Platelet-Derived Growth Factor - metabolism; Receptor, Platelet-Derived Growth Factor alpha - metabolism; Receptor, Platelet-Derived Growth Factor beta - metabolism; Taxoids - pharmacology; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 0250-7005; 1791-7530

Head and neck squamous cell carcinoma (HNSCC) is the most common malignant epithelial tumor in the upper aerodigestive tract. The incidence of HNSCC induced by the oncogenic human papilloma virus (HPV) is rising, indicating a growing importance of the viral etiology. Cell proliferation, migration and tumor vascularization are regulated by a set of angiogenic peptides such as PDGF (platelet-derived growth factor), PDGFRα/β (platelet-derived growth factor receptor α/β) and VEGF (vascular endothelial growth factor). In locally advanced HNSCC docetaxel is used for induction chemotherapy (ICT) combined with platinum-based chemotherapy and 5-fluorouracil (5-FU). This study sought to evaluate the expression of angiogenic factors (VEGF, PDGF and PDGFRα/β) in HPV-positive (CERV196) and HPV-negative squamous cell carcinoma (HNSCC 11A and 14C) and the efficacy of chemotherapy with docetaxel as a potential treatment modality, compared to 5-FU as a single-drug application. Tumor cell lines were incubated with 5-FU or docetaxel at a concentration of 1.0 and 5.0 μmol/ml. Enzyme-linked immunosorbent assay (ELISA) and immunohistochemical analyses were carried out after 48, 72, 120, 192 and 240 hours, in order to identify changes in protein expression of VEGF, PDGF and PDGFRα/β. We demonstrated a significant reduction of VEGF and PDGFRβ expression after incubation with docetaxel by ELISA and of PDGF by immunohistochemistry, irrespective of the HPV status, whereas the application of 5-FU had a significantly weaker impact on the expression of angiogenic peptides. HPV-positive CERV196 cells were characterized by a reduced susceptibility to a docetaxel-altered expression. Although neither of the applied drugs are selective anti-angiogenic agents, docetaxel surprisingly was demonstrated to cause a significant decrease of angiogenic factors in this study.